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Background: There are conflicting data regarding
he benefits of omega-3 (n-3) fatty acids, most recently
n patients with type 2 diabetes.
Objective: Our goal was to evaluate the impact of
icensed, highly purified n-3 fatty acids on all-cause
ortality after myocardial infarction (MI).
Methods: This was a retrospective, matched-cohort
tudy using data from the General Practice Research Da-
abase. Patients initiating treatment with 1 g of n-3 fatty
acids in the 90 days after firstMIwere identified and each
matched to 4 nonexposed patients. Progression to death
was compared using time-dependent Cox models to ac-
count for potential differences in exposure to other
cardiovascular risk–modifying treatments.
Results: A total of 2466 eligible subjects exposed to
n-3 fatty acids were matched. The majority of patients
had concurrent treatment with lipid-lowering thera-
pies, antihypertensives, and antiplatelets after first MI,
with subjects exposed to n-3 fatty acids having a
greater likelihood of concurrent exposure. For those
initiating n-3 fatty acids within 90 days of first MI, the
adjusted hazard ratio (aHR) was 0.782 (95% CI,
0.641–0.995; P  0.0159); for those initiating treat-
ment within 14 days, the aHR was 0.680 (95% CI,
0.481–0.961; P  0.0288). In patients with type 2
diabetes at baseline, the aHRs were 0.714 (95% CI,
0.454–1.124) and 0.597 (95%CI, 0.295–1.211) when
initiation was within 90 and 14 days, respectively. Use
of n-3 fatty acids resulted in a consistent survival ben-
efit under a range of scenarios quantitatively consistent
with the overall effect.
40Conclusion: After MI, early treatment with licensed
n-3 fatty acids was associated with improvement in
all-cause mortality in patients with and without type 2
diabetes, against a background of contemporary
cardiovascular risk–modifying treatments. (Clin Ther.
2013;35:40–51) © 2013 Elsevier HS Journals, Inc. All
rights reserved.
Key words: all-cause mortality, n-3 fatty acids,
omega-3 fatty acids, ORIGIN trial, type 2 diabetes.
INTRODUCTION
Essential omega-3 (n-3) fatty acid supplementation is
associated with improved endothelial and myocardial
function and with triglyceride-lowering, anti-inflam-
matory, antithrombotic, and antiarrhythmogenic effects.
High dietary intake of oily fish, and thus marine-derived
n-3 fatty acids, is also associated with improved cardio-
vascular disease (CVD) outcomes.1,2 Several large ran-
domized studies have shown significant improvements in
mortality and a reduction in major CVD events after
treatment with n-3 fatty acids.3–5 Meta-analyses of
such randomized studies have typically demon-
strated a beneficial impact on CVD outcomes; how-
ever, there are inconsistencies in terms of methods
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C.D. Poole et al.and outcomes.2,6–8 The studies integral to these meta-
analyses were heterogeneous: conducted in different
populations with postacute or distant myocardial in-
farction (MI), stable coronary artery disease, heart fail-
ure, implantable cardioverter defibrillators, post-
stroke, and in those at high CVD risk. Furthermore,
included studies evaluated varying doses of n-3 supple-
ments (400–4800 mg n-3 fatty acids per day) and dif-
fering supplements (fish, fish oil, highly purified n-3
ethyl esters, and aminolevulinic acid) and had various
trial durations.
Most recently, the ORIGIN (Outcome Reduction
With Initial Glargine Intervention) trial evaluated the im-
pact of n-3 fatty acids versus placebo on the risk of pro-
gression to all-cause mortality and major cardiovascular
events in individuals with dysglycemia.9 ORIGIN re-
orted no difference in risk between the drug and pla-
ebo in 12,000 subjects, with an average 6 years of
ollow up.
The product evaluated in ORIGIN was a highly pu-
ified, stable preparation of 460 mg of eicosapenta-
noic acid and 380 mg of docosahexaenoic acid ethyl
sters; it is the only n-3 fatty acid licensed for use as
djuvant treatment in the secondary prevention of MI,
hich was one of the subpopulations studied in the
RIGIN study. Only 59.1% of patients in the n-3 fatty
cid arm had an MI, stroke, or revascularization.10
The product license was based on the findings from the
large GISSI-Prevenzione (GISSI-P) study,4 which dem-
onstrated a reduction of 20% in all fatal events, in
large part due to a 45% reduction in sudden cardiac
death in patients treated with 1 g/d of n-3 fatty acids
within 90 days of an acute MI.
The purpose of the current study was to compare
survival rates after treatment with licensed n-3 fatty
acids in routine clinical practice in individuals with and
without diabetes who survived their first MI, adjusting
for other clinical variables and cardiovascular risk–
modifying medications.
METHODS
This retrospective, matched-cohort study used data
from the General Practice Research Database (GPRD;
replaced by the Clinical Practice Research Datalink
fromApril 2012). GPRD is a longitudinal, anonymized
database derived from nearly 700 primary care prac-
tices throughout the United Kingdom that are broadly
geographically and demographically representative of
the country as a whole. At the time of the study, GPRD
January 2013contained clinical records from 11 million individu-
als, of whom 5 million were actively registered. The
data captured by GPRD include demographic charac-
teristics, medical history, clinical investigations, and
drug prescriptions. The routine data are recorded elec-
tronically in general practice andmonitored for quality
by the UK Medicines and Healthcare products Regu-
latory Agency (MHRA). Diagnoses in GPRD are re-
corded by using the Read code classification and have
been validated in a number of studies, with results
showing a high positive predictive value.11
Studies using the GPRD/Clinical Practice Research
Datalink are covered by ethics approval granted by the
Trent Multicentre Research Ethics Committee (refer-
ence 05/MRE04/87). The current study was granted
MHRA Independent Scientific Advisory Committee
approval (ISAC 12_033).
Selection of Patients With a First MI
The study population comprised patients diagnosed
with a first MI whose records had been assessed by the
MHRA as meeting research-quality standards. To en-
sure that the first identified MI was indeed the first
occurrence, patients were excluded if the description of
the MI implied the existence of a previous infarction
event, if patients had been registered at the practice for
180 days before the MI, or if the practice was judged
by the MHRA to be recording up-to-standard data for
180 days before that event. Patients were selected if
they were prescribed highly purified n-3 fatty acids ap-
proved in the United Kingdom for secondary preven-
tion after MI at a daily dose of 1 g. Patients were
excluded from the study if they were prescribed fish-
derived n-3 fatty acid preparations not licensed for
post-MI secondary prevention at any time after their
first MI. People with diabetes other than type 2 were
excluded. A flow diagram illustrating patient selection
is detailed in Figure 1.
Treatment Cohort Selection and Comparative
Analysis
From this general study population, a cohort was
identified of patients exposed to 1 g of n-3 fatty acids
for the first time on or after their first MI (the index
date). We restricted our analysis to treatment initiation
within the recommended time of 90 days12 and con-
ducted a sensitivity analysis on those initiating treat-
ment with n-3 fatty acids within 14 days. Patients were
41
ft
y
i
i
f
a
j
a
e
a
w
i
c
L
t
d
s
Clinical Therapeuticsexcluded from the cohort if any prescription stipulated
a daily dose of1 g, which would imply an indication
other than secondary prevention, or if the daily dose
could not be determined. Patients were also excluded if
they were prescribed n-3 fatty acids subsequent to a
Excluded: Patients with either
unknown type or type 1
diabetes before ﬁrst MI
n = 42
Excluded: Patients prescribed
n-3 FA ≥ 90 days after 1st MI
n = 591
Patients prescribed n-3 FA
within  90 days of ﬁrst MI
n = 2466
Patients either with no
diabetes or type 2 diabetes
before ﬁrst MI
n = 3057
Patients registered at practice 
≥180 days before ﬁrst MI
n = 155,595
Patients with record of
nonfatal MI
n = 226,510
Research-quality patients
in GPRD at December 2011
n = 11,801,879
Excluded: Patients with ﬁrst
MI before 01/01/2002
n = 246
Excluded: Patients not
successfully matched 1:4 with
nonexposed patients
n = 164
Excluded: Patients prescribed
>1g/d n-3 FA
n = 627
Excluded: Patients prescribed
ﬁsh-derived n-3 FA after ﬁrst MI
n = 11
Excluded: Patients never 
prescribed n-3 FA or prescribed
n-3 FA prior to ﬁrst MI
n = 102,641
Excluded: Patients at practices 
recording up-to-standard data
<180 days before ﬁrst MI
n = 48,807
Excluded: Patients registered at
practice <180 days before
ﬁrst MI
n = 70,915
Excluded: Patients with no record
of MI, only fatal MI recorded, or
ﬁrst MI of uncertain date
n = 11,575,369
Patients whose ﬁrst MI
occurred after 12/31/2001
n = 3099
Patients successfully matched
1:4 with nonexposed patients
n = 3345
Patients prescribed highly
puriﬁed 1 g/d of n-3 FA
n = 3509
Patients prescribed highly
puriﬁed  n-3 FA after ﬁrst MI 
n = 4136
Patients prescribed n-3 FA
for the ﬁrst time on or after
ﬁrst MI
n = 4147
Patients at practices recording
up-to-standard data for
≥180 days before ﬁrst MI
n = 106,788
Figure 1. Patient flow diagram for selection of pa-
tients exposed to omega-3 fatty acids
(n-3 FA). MI  myocardial infarction.urther cardiovascular event (Figure 1). o
42Matching Procedure
Each member of the exposed cohort was matched,
at random, to 4 patients from the remaining study pop-
ulation who had experienced a previous MI and had
not been exposed to n-3 fatty acids. They were
matched on the following criteria: sex, year of birth
(2 years), year of first MI, smoking status, type 2
diabetes status, registration with a differing general
practice (to minimize confounding by indication), and
a period of follow-up from their first MI not less than
the interval between first MI and first n-3 fatty acid
prescription in the corresponding exposed patient (to
minimize immortal time bias).
The primary end point for this study was all-cause
mortality as recorded in GPRD.Mortality was identified
from the Read codes recorded in GPRD and from linked
Office of National Statistics (ONS) mortality records.
Modeled Comparison of Survival
To determine if there was any identifiable residual
confounding and to allow for changes in treatment and
other mortality/CVD risk factors after the initial MI
event, time-dependent Coxmodels were used. This mod-
eling was potentially important in accounting for differ-
ences after the index date, such as exposure to other
cardiovascular risk–modifying medications (eg, statins).
Covariates considered for inclusion in the Coxmodels
were age, sex, diabetes, systolic blood pressure, total cho-
lesterol, body mass index, smoking status, lipid-lowering
therapy, antiplatelet therapy, and antihypertensive ther-
apy (incorporating use of -blockers and drugs affecting
he renin–angiotensin system). After a preliminary anal-
sis, a number of covariates were selected and then
ncluded in all of the models. Year of n-3 fatty acid
nitiation was also included in the models to account
or any temporal effects. Baseline morbidity was char-
cterized using the Charlson comorbidity index. Sub-
ects with missing data were automatically excluded,
nd the proportional hazards assumption was consid-
red by evaluation of the Kaplan-Meier curves and
nalysis of the Schoenfeld residuals. Survival patterns
ere evaluated under a number of alternative scenar-
os, including: aspirin and clopidogrel monotherapy or
ombination therapy, individual statin type, baseline
DL-C subgroup, achieved LDL-C subgroup, and
hose who were ever or never diagnosed with type 2
iabetes. This latter scenario violated a theoretical as-
umption of the survival model13 but was nevertheless
f interest.
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C.D. Poole et al.Table I. Baseline characteristics at first myocardial infarction for those with and without type 2 diabetes at
baseline, exposed and nonexposed to omega-3 (n-3) fatty acids.
Characteristic
No Previous Type 2 Diabetes Previous Type 2 Diabetes
Exposed Nonexposed P Exposed Nonexposed P
No. of patients 2140 8429 326 1283
Male sex, % 71 71 0.925 73 73 0.925
Age, mean (SD), y 63.34 (12.40) 63.30 (12.33) 0.900 67.88 (10.98) 67.72 (10.87) 0.805
Socioeconomic status, %, IMD quintile
1 14 22 0.001 14 18 0.010
2 20 22 17 22
3 18 19 16 21
4 20 21 24 21
5 (most deprived) 27 15 29 19
Index year of first MI, %
2002 1 1 0.999 1 1 0.999
2003 1 1 2 2
2004 6 6 3 3
2005 6 6 6 6
2006 7 7 5 5
2007 11 11 10 11
2008 15 15 15 15
2009 21 21 21 21
2010 21 21 24 24
2011 12 12 13 13
Smoking status, %
Never smoked 30 30 0.997 28 28 0.992
Ex-smoker 31 31 49 49
Current smoker 39 39 23 23
BMI, mean (SD), kg/m2 27.35 (5.81) 27.27 (6.38) 0.716 29.97 (5.64) 29.65 (6.22) 0.455
Blood pressure, mean (SD), mm Hg
SBP 132.24 (21.03) 133.09 (20.91) 0.121 134.42 (21.28) 134.67 (21.63) 0.858
DBP 77.03 (12.29) 77.17 (12.03) 0.665 75.97 (11.92) 75.52 (12.41) 0.575
Serum cholesterol, mean (SD), mmol/L
Total cholesterol 5.10 (1.32) 5.08 (1.32) 0.660 4.50 (1.19) 4.45 (1.14) 0.571
HDL-C 1.25 (0.36) 1.28 (0.39) 0.020 1.14 (0.30) 1.15 (0.35) 0.585
LDL-C 3.04 (1.09) 3.06 (1.08) 0.743 2.53 (0.95) 2.52 (0.97) 0.923
Triglycerides, mean (SD), mmol/L 1.72 (0.92) 1.67 (0.92) 0.212 1.93 (0.92) 1.91 (1.02) 0.744
GP contacts in year prior, median (IQR) 6 (2–12) 6 (2–13) 0.619 12 (7–20) 12 (6–22) 0.851
Charlson comorbidity index, median (IQR) 1 (1–2) 1 (1–2) 0.031 3 (2–5) 4 (2–5) 0.216
Diabetes-specific details
HbA1c, mean (SD), % 7.56 (1.59) 7.65 (1.76) 0.521
Previous diabetes therapy, %
Lifestyle 40 35 0.110
OHA monotherapy 29 28
OHA combination therapy 18 19
Injected therapy 14 19
Diabetes duration, median (IQR), y 5.44 (1.86–9.91) 6.06 (2.13–11.82) 0.059
IMD  index of multiple deprivation; MI  myocardial infarction; BMI  body mass index; SBP  systolic blood pressure; DBP 
diastolic blood pressure; GP  general practitioner; IQR  interquartile range; HbA1c  hemoglobin A1c; OHA  oral hypoglycemic
agent.January 2013 43
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Clinical TherapeuticsRESULTS
Patients and Baseline Characteristics
We identified 2466 eligible first-MI patients subse-
quently exposed to n-3 fatty acids; 326 (13%) had a
baseline diagnosis of type 2 diabetes. These patients
were matched in a 1:4 ratio to similar patients who had
not been prescribed n-3 fatty acids post-MI. In the non-
diabetes group, the mean (SD) age was 63 (12) years,
and 71% were male. The matching was appropriate,
resulting in very similar characteristics (Table I), al-
though patients exposed to n-3 fatty acids had worse so-
cioeconomic status, generally regarded as an indicator of
increased mortality risk.14 In those with previous type 2
iabetes, the duration of diabetes in the nonexposed co-
ort was arguably slightly longer, with a mean duration
f 6.1 years versus 5.4 years (P  0.059); however, the
matching procedure was otherwise consistent.
Treatment With Other Cardiovascular
Risk–Modifying Treatments After MI
The majority of post-MI patients had concurrent
treatment with lipid-lowering therapies, antihyperten-
sives, and antiplatelets after their first MI. This varied
slightly between the various comparator groups used
in this study (Table II): patients exposed to n-3 fatty
acids had a greater likelihood of concurrent exposure
to these treatments. Within 90 days in those without
diabetes, 98% of exposed patients had received lipid-
lowering drugs versus 84% in the nonexposed patients
(P  0.0001); for antihypertensive agents, the propor-
Table II. Exposure to omega-3 (n-3) fatty acids and c
infarction.
Drug Class
No Diabet
Exposed Nonexpose
Exposure within 90 days
Lipid-lowering drugs, % 97.6 84.0
Antihypertensives, % 98.5 86.6
Antiplatelets, % 98.3 84.9
Exposure within 12
months
Lipid-lowering drugs, % 92.4 79.1
Antihypertensives, % 95.3 82.9
Antiplatelets, % 94.2 79.6ions were 99% versus 87% (P  0.0001), respec-
44tively, and for antiplatelet drugs, it was 98% versus
85% (P  0.0001). Thus, it was necessary to account
for these factors by using the multivariate, time-depen-
dent models.
Time To Initiation of n-3 Fatty Acid Treatment
Of those patients treated with n-3 fatty acids, 82%
ad their treatment initiated in the 90 days after first MI,
n line with recommendations and justifying the selection
f these subjects for this study.12 Figure 2 illustrates the
cumulative percentage of time to treatment initiation
from the first event. Those in the lower tertile of time to
initiationwere also selected for a sensitivity analysis look-
vascular risk–modifying treatments after myocardial
Previous Type 2 Diabetes
P Exposed Nonexposed P
0.0001 96.2 82.8 0.0001
0.0001 98.1 87.9 0.0001
0.0001 97.8 83.2 0.0001
0.0001 91.7 77.9 0.0001
0.0001 95.2 84.7 0.0001
0.0001 88.9 78.8 0.0001
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Figure 2. Time to treatment initiation with ome-
ga-3 (n-3) fatty acids after first myocar-
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C.D. Poole et al.ing at early time to treatment initiation (range, 0–13
days; median, 7 days). Excluded patients, prescribed li-
censed n-3 fatty acids but with initial exposure90 days
ost-MI, represented 17.9% of patients.
Crude Survival Patterns
Overall, there were 1517 recorded deaths (12.5%of
patients). Crude event rates differed according to dia-
betes status and n-3 fatty acid exposure status. In those
exposed to n-3 fatty acids, the crude event rates were
61/1000 person-years for those with type 2 diabetes at
baseline and 33/1000 person-years for those without
diabetes at baseline. In those not exposed to n-3 fatty
acids, the crude event rates were 90/1000 person-years
for those with type 2 diabetes at baseline and 46/1000
person-years for those without. These data resulted in
crude relative risk values of 0.708 (95% CI, 0.602–
0.833; P  0.0001) overall, and 0.686 (95% CI,
0.504–0.934; P 0.0166) for those with diabetes and
.724 (95% CI, 0.621–0.844; P  0.0001) for those
without diabetes, respectively (Table III).
Adjusted Survival Patterns
All of the selected covariates were important in the
Table III. Number of events and crude relative risk val
fatty acids.
Parameter
All patients
No. of death events
Total follow-up, y
Deaths per 1000 person-years, no.
Crude relative risk (95% CI)
Patients with no previous diabetes
No. of death events
Total follow-up, y
Deaths per 1000 person-years, no.
Crude relative risk (95% CI)
Patients with previous type 2 diabetes
No. of death events
Total follow-up, y
Deaths per 1000 person-years, no.
Crude relative risk (95% CI)model in specifying the risk of death, including expo- p
January 2013sure to all classes of cardiovascular risk–modifying
agent (Table IV).
The adjusted hazard ratio (aHR) for all-cause mor-
tality was consistently lower among those exposed to
n-3 fatty acids, and materially did not differ among
those with and without diabetes at baseline survey or
in those who developed diabetes during follow-up (Fig-
ure 3). When the models were restricted to those who
initiated therapy within 14 days, the strength of asso-
ciation for those exposed to n-3 fatty acids seemed
modestly stronger across the range of subgroups.
The fully specified, time-dependent Cox models
evaluating n-3 fatty acid exposure within 90 days and
within 14 days are detailed in Table IV. The aHRs for
these two scenarios were 0.782 (95% CI, 0.641–
0.995; P  0.0159) and 0.680 (95% CI, 0.481–0.961;
P 0.0288), respectively. In those with type 2 diabetes
at baseline, the aHR seemed modestly stronger com-
pared with those without diabetes: 0.714 (95% CI,
0.454–1.124; P  0.1453) when initiating n-3 fatty
cids within 90 days and 0.597 (95%CI, 0.295–1.211;
 0.1532) when initiating within 14 days (Figure 3).
The association between use of n-3 fatty acids and
educed mortality hazard remained constant at ap-
r patients exposed and not exposed to omega-3 (n-3)
Exposed Nonexposed
2466 9712
243 1274
6668 24,943
36.4 51.1
.708 (0.602–0.833) P  0.0001
2140 8429
195 1016
5882 22,066
33.2 46.0
.724 (0.621–0.844) P  0.0001
326 1283
48 258
786 2878
61.1 89.7
.686 (0.504–0.934) P  0.0166ues fo
0
0
0roximately –20%, regardless of time-dependent ad-
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Clinical Therapeuticsjustment for the following: concurrent antiplatelet (yes
vs no, aspirin yes vs no and clopidogrel yes vs no, or no
therapy vs aspirin/clopidogrel monotherapy vs combi-
nation therapy); lipid-lowering strategies (statin yes vs
no, or agent specific); and baseline LDL-C subgroup
(Joint British Societies’ target level of 1.8 mmol/L vs
an intermediate level of 1.8–3.0 mmol/L vs high-range
level of3.0 mmol/L) (Figure 4). In analyses stratified
according to on-treatment LDL-C subgroup, there was
no materially significant difference in observed sur-
vival benefit from n-3 fatty acids exposure (Figure 5).
Similarly, when the association between n-3 fatty acid
exposure was compared among those receiving single
Table IV. Time-dependent Coxmodels of the hazard o
fatty acids initiated within 90 and 14 days
nonexposed patients.
Model Parameter
Initiation
HR 95%
Time-dependent covariates
(quarterly periods)
n-3 fatty acid exposure, 1 g/d,
yes/no
0.782 0.641–
Lipid-lowering drug exposure,
yes/no
0.433 0.373–
Antihypertensive exposure,
yes/no
0.416 0.358–
Antiplatelet exposure, yes/no 0.563 0.485–
Time-fixed covariates (at first MI)
Age, y 1.069 1.064–
Smoking status vs never
Ex-smoker 1.255 1.112–
Current smoker 1.454 1.255–
Socioeconomic status, IMD
quintile vs group 1
2 1.105 0.902–
3 1.246 1.018–
4 1.251 1.024–
5 (most deprived) 1.399 1.145–
Missing 1.118 0.941–
Charlson comorbidity index,
per unit
1.251 1.224–
HR  hazard ratio; IMD  index of multiple deprivation.or dual antiplatelet therapy, a consistent benefit was
46observed with n-3 fatty acid exposure. There was no
evidence of any significant additional survival benefit
in the excluded patients exposed to initial treatment
with n-3 fatty acids after 90 days (aHR 1.281 [95%
CI, 0.750–2.190]; P  0.365; nexposed  538). It is
orth noting that some of these patients were likely to
ave initiated n-3 fatty acids after a subsequent event.
DISCUSSION
This real-world evaluation of clinical practice comple-
ments randomized trial data by demonstrating that
treatment with licensed n-3 fatty acids was associated
with reduced all-cause mortality when initiated early
ausemortality for patients exposed to omega-3 (n-3)
eir first myocardial infarction (MI) versus matched,
Days Initiation 14 Days
P HR 95% CI P
0.0159 0.680 0.481–0.961 0.0288
0.0001 0.445 0.346–0.571 0.0001
0.0001 0.425 0.331–0.546 0.0001
0.0001 0.535 0.415–0.690 0.0001
0.0001 1.060 1.051–1.068 0.0001
0.0001 0.0704
0.0002 1.222 1.003–1.488 0.0469
0.0001 1.273 1.002–1.617 0.0482
0.0131 0.7815
0.3352 1.166 0.842–1.615 0.3547
0.0331 1.079 0.774–1.502 0.6550
0.0280 1.031 0.741–1.434 0.8566
0.0010 1.236 0.896–1.706 0.1968
0.2055 1.073 0.810–1.421 0.6218
0.0001 1.239 1.197–1.282 0.0001f all-c
of th
90
CI
0.955
0.503
0.483
0.653
1.074
1.417
1.684
1.353
1.525
1.527
1.708
1.327
1.278post-MI. Our data are concordant with the 20% re-
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C.D. Poole et al.duction in all-cause mortality reported in the GISSI-P
trial.4 In our study, treatment initiation with licensed,
ighly purified n-3 fatty acids within 90 days ofMIwas
ssociated with a reduction in risk of all-cause mortal-
ty of 21.8%, independent of other cardiovascular
isk–modifying treatments. Our data also demon-
trated that earlier treatment initiation, within the 14
ays after MI, seemed to increase survival benefit by as
uch as 40%, the inference being that n-3 fatty acid
reatment should be initiated as soon as possible. The
mpact on outcome was similar in those with and with-
ut type 2 diabetes and independent of other evidence-
ased, secondary-prevention medication strategies.
The European Society of Cardiology, the American
Analysis
n-3 FA initiated within 90 days of MI
n-3 FA initiated within 14 days of MI
All patients (1)
No DM at index (2)
T2DM at index (3)
Never T2DM (4)
Ever T2DM (5)
All patients (6)
No DM at index (7)
T2DM at index (8)
Never T2DM (9)
Ever T2DM (10)
Hazard
0.2
Favo
Treatm
Figure 3. Summary of the time-dependent Cox mode
sure hazard ratio for all-cause mortality for
partially violate an assumption of the surviv
baseline characteristic but are of interest. P
1. Base analysis for all patients initiating n
Table IV for model specification (n  1
2. Subgroup analysis of (1) who had no his
P  0.054).
3. Subgroup analysis of (1) who had evide
0.145).
4. Subgroup analysis of (1) who had no e
5. Subgroup analysis of (1) who had evide
6. Base analysis for all patients initiating
specification (n  4107; P  0.029).
7. Subgroup analysis of (6) who had no h
8. Subgroup analysis of (6) who had evide
9. Subgroup analysis of (6) who had no e
10. Subgroup analysis of (6) who had evideeart Association, and other national cardiac societies
January 2013ave evaluated the evidence and converged on a rec-
mmendation for post-MI patients to consume 1 g of
-3 fatty acids per day.15–17 The current study confirms
that, although not all UK patients receive licensed n-3
supplements post-MI, physicians are prescribing in line
with the licensed indication and National Institute for
Health and Clinical Evidence (NICE) guidelines,12
with the majority of patients treated with n-3 fatty
acids receiving them within 90 days and also being
treated with other evidence-based cardiovascular risk–
modifying therapies. Although the adjusted models ac-
counted for variations in clinical factors and concom-
itant medication use, it would have been of interest to
examine individuals exposed to n-3 fatty acids but not
0.782 (0.641–0.955)
0.803 (0.643–1.004 )
0.714 (0.454–1.121)
0.754 (0.593–0.958)
0.831 (0.572–1.205)
0.680 (0.481–0.961)
0.731 (0.492–1.086)
0.597 (0.295–1.211)
0.658 (0.427–1.012)
0.778 (0.434–1.394)
and 95% CI
5
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Hazard Ratio and 95% CI
wing the adjusted omega-3 fatty acid (n-3 FA) expo-
ring scenario groups. Analyses (4), (5), (9), and (10)
del by specifying emergence of diabetes (or not) as a
3 FA parameter estimate.
within 90 days of first myocardial infarction (MI); see
8; P  0.016).
f diabetesmellitus (DM) before firstMI (n 10,569;
f type 2 DM (T2DM) before first MI (n 1609; P
ce of T2DM at any time (n  9581; P  0.021).
f T2DM at any time (n  2565; P  0.328).
A within 14 days of first MI; see Table IV for model
of DM before first MI (n  3474; P  0.121).
f T2DM before first MI (n  633; P  0.153).
ce of T2DM at any time (n  3152; P  0.056).
f T2DM at any time (n  1010; P  0.398). Ratio 
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Clinical Therapeuticsantihypertensive agents as a single drug class, but this
class included drugs such as -blockers, angiotensin-
converting enzyme inhibitors, and angiotensin II recep-
tor blockers that are typically used routinely in second-
ary prevention post-MI regardless of whether the
patient is hypertensive.
This epidemiologic study also provides an impor-
tant evidential adjunct to existing randomized data in
that it illuminates some potential limitations in rele-
vant randomized trial designs. Themost recent study—
the ORIGIN trial—showed no difference in those with
dysglycemia exposed to treatment with n-3 fatty acids
versus placebo.9 However, as we found no benefit in
patients who initiated their n-3 fatty acid treatment
after the recommended 90-day period, the question
remains whether this may have been the case for the
patients recruited in ORIGIN, considering that no in-
formation related to the time of initiation of n-3 fatty
acids post-MI was provided in the publication. Al-
Analysis
Base analysis*
Antiplatelet sensitivity analysis (1)
Antiplatelet sensitivity analysis (2)
Statin type sensitivity analysis (3)
Baseline LDL-C subgroup analysis (4)
Post-MI LDL-C sensitivity analysis (5)
Hazard
0.2
Favo
treatm
Figure 4. Sensitivity analyses showing the adjusted o
cause mortality for differing parameter mo
initiating n-3 FA within 90 days of myocard
parameter estimate.
1. Antiplatelet (yes vs no) substituted by as
P  0.030).
2. Antiplatelet (yes vs no) substituted by no
plus clopidogrel combination therapy) (
3. Lipid-lowering therapy (yes vs no) substi
plus ezetimibe vs atorvastatin vs rosuvas
4. Additional time-fixed parameter, basel
of1.8 mmol/L vs intermediate level of
4006; P  0.082).
5. Additional time-variable parameter, pos
(n  6004; P  0.047).though our study had only small numbers in the type 2 t
48diabetes group, we observed that the magnitude of ef-
fect was similar in those with diabetes and in those
without for all-cause mortality.
Importantly, this study evaluated all-cause mortal-
ity as an end point and not CVD events.We believe this
to be important because one of the principal mecha-
nisms of action of n-3 fatty acids is thought to be their
antiarrhythmogenic properties.1 In almost all study
cenarios, this represents a potential reporting bias in
hat the probability of experiencing a nonfatal MI
vent could therefore be increased in those exposed to
-3 fatty acids. Use of death as the outcome avoids this
otential bias and also protects against the issue of
ompeting risks.
This study had inherent limitations. Because study
atients were not randomized to treatment, there could
e confounding by indication (or allocation bias), and
here will in all probability remain residual confound-
ng (accounting for nonrecorded factors). Nonetheless,
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and 95% CI
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-3 fatty acid (n-3 FA) exposure hazard ratio for all-
g. *Model specification shown in Table IV for those
farction (MI) (n  12,178; P  0.016). P  n-3 FA
(yes vs no) and clopidogrel (yes vs no) (n 12,178;
py versus aspirin/clopidogrel monotherapy vs aspirin
2,178; P  0.028).
by statin therapy (none vs simvastatin vs simvastatin
vs other statin) (n  12,178; P  0.034).
DL-C subgroup (Joint British Societies’ target level
.0 mmol/L vs high-range level of3.0 mmol/L) (n
quarterly updated LDL-C subgroup (as in [4] above) Ratio 
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C.D. Poole et al.two covariates (ONSmortality and socioeconomic sta-
tus) were provided by GPRD only after the specific
study patients had been identified and matched; thus,
these factors could not be used in thematching process.
Interestingly, the patients exposed to licensed n-3 fatty
acids were of lower socioeconomic status. This may be
associated with general practitioners being aware of
the potential benefits of n-3 fatty acids and therefore
rescribing treatment on the understanding that the
atient may not otherwise be able or willing to access
arine n-3 fatty acids through diet or otherwise. In-
eed, in the Euroaction Study, only 11% of patients in
eneral practice achieved their recommended level of
-3 fatty acids by dietary means.18 We have not exam-
ned the association between n-3 fatty acids and major
onfatal cardiovascular events, such as further acute
oronary syndrome, need for subsequent percutaneous
oronary intervention or coronary artery bypass graft,
Analysis
Pre-MI classiﬁcation
Baseline LDL-C subgroup (pooled; 1)
BL LDL-C <1.8 mmol/L (2)
Post-MI classiﬁcation: antiplatelet therapy
Antiplatelet monotherapy (5)
Aspirin+clopidogrel combination (6)
BL LDL-C <1.8 to 3.0 mmol/L (3)
Post-MI classiﬁcation: LDL-C control in year 1
JBS target (<1.8 mmol/L (7)
Intermediate (1.8 – 3.0 mmol/L (8)
High range (>3.0 mmol/L (9)
BL LDL-C >3.0 mmol/L (4)
Ha
0.2
F
Tre
Figure 5. Subgroup analyses using time-dependent C
exposure hazard ratio for all-cause mortalit
1. Base analysis (specified in Table IV) str
observation-carried-forward from up to
P  0.095).
2. Joint British Societies’ (JBS) target (1.8
3. Intermediate level (1.8–3.0 mmol/L) BL
4. High-range level (3.0 mmol/L) BL LDL
5. Patients initiating aspirin or clopidogrel
0.260).
6. Patients initiating aspirin and clopidogre
7. Patients achieving JBS target LDL-C in fir
8. Patients with intermediate LDL-C in first
9. Patients with high-range LDL-C in first yr recurrence of angina or stroke; this association was m
January 2013utside the remit of this already extensive analysis.
owever, the results of GISSI-P and other studies
ould lead us to expect less of an effect on these out-
omes with this dose of n-3 fatty acids.4,5,19 In addi-
tion, when viewed from a data perspective, case ascer-
tainment for recurrent events can be difficult to
distinguish from a recording of medical history. There-
fore, we selected an index event (first MI) and primary
end point (any death), each of which could be identi-
fied with a high degree of confidence.
Recent trials, such as OMEGA and ORIGIN, and a
meta-analysis have suggested a lack of benefit of n-3
fatty acids in secondary prevention of cardiovascular
disease in different patient populations.9,20,21 In part,
t was postulated (methodologic differences aside) that
his may reflect a lack of benefit against a background
f intensive modern preventative therapy. In the cur-
ent study, we report on 1517 deaths, almost 10 times
0.768 (0.594–1.047)
1.257 (0.663–2.381)
0.825 (0.590–1.153)
0.786 (0.605–1.022)
0.678 (0.426–1.078)
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omega-3 fatty acid parameter estimate.
d according to baseline (BL) LDL-C subgroup (last-
r before index); pooled effect over strata (n  4006;
ol/L) BL LDL-C subgroup (n  579; P  0.484).
C subgroup (n  1704; P  0.101).
bgroup (n  1723; P  0.161).
otherapy within 3 months after MI (n  2702; P 
apy within 3 months after MI (n 7834; P 0.072).
r after MI (month 1 excluded; n 2433; P 0.070).
after MI (month 1 excluded; n  3057; P  0.531).
ter MI (month 1 excluded; n  501; P  0.358).zard R
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ear afore deaths than in the OMEGA trial (although the
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Clinical Therapeuticsannual death rates were similar at 4.8% and 4.2%,
respectively), suggesting our study is both representa-
tive and adequately powered. In the sensitivity analysis
among those receiving dual antiplatelet therapy and
those achieving low levels of LDL-C (1.8 mmol/L),
we observed no significant modification of the benefi-
cial effect of n-3 fatty acid exposure on mortality (Fig-
ures 4 and 5). Taken together, the current data suggest
that when n-3 fatty acids are prescribed within 90 days
(and in particular within 14 days) of an MI, this inter-
vention offers additional protection against all-cause
mortality on top of contemporary pharmacotherapy.
In GPRD, linking to ONS mortality records in-
creases the frequency of death events by 10%. This
has a subtle technical impact on this type of study in
that it introduces a potential immortal time bias in a
very small number of the nonexposed, matched pa-
tients because they were subsequently determined to
have died before thematching patient was first exposed
to the treatment of interest. These corresponding ex-
posed and nonexposed subjects were excluded. A fur-
ther, subtle limitation of these data relates to the date
of the record of MI on the general practitioner’s
computerized systems. Although we have assumed
that the general practitioner has recorded the correct
date of the MI from the discharge letter or in discus-
sion with the patient, it is plausible—if not likely—
that some of the MI event dates referred to the date
at which the general practitioner entered the data
onto their system. This would have the impact of
slightly shortening the calculated time to treatment
initiation that we report here.
These findings have important treatment implications.
First, they help explain why some of the clinical trials
have resulted in conflicting and sometimes neutral find-
ings. Although we did not examine for dose effects, the
timingof administrationofn-3 fatty acid treatment seems
relevant for optimizing survival benefit in secondary-pre-
vention patients post-MI. Very early administration after
hospital admission of higher doses of the licensed n-3
fatty acids should be evaluated.
CONCLUSION
In routine clinical practice, early treatment with li-
censed n-3 fatty acids after a nonfatal MI was associ-
ated with a substantial reduction in risk of death, in-
dependent of other cardiovascular risk–modifying
treatments, in patients with and without type 2
diabetes.
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